HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

Inclusion Criteria: * Age (18-75 years controls, early/late premanifest HD and incomplete penetrance HD, 21-75 years early/moderate/advanced manifest HD, ≥11 years juvenile HD) * Enroll HD participant * Capable of consenting or have a legal representative (parent/guardian for juveniles) * Capable of complying with study procedures * All participants other than family and community controls must have had a genetic test for HD Exclusion Criteria: * Drug trial within 30 days of any sampling visit * Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days) * Antiplatelet or anticoagulant therapy within 14 days * Significant comorbidity * Needle phobia, headache, spinal surgery / deformity * Clotting or bruising disorder * Screening blood test abnormalities \>10% outside normal range * Drug / alcohol abuse * Positive urine pregnancy test at any screening or sampling visit for females of childbearing potential * Predictable non compliance or unwillingness * Serious adverse event related to HDClarity study procedures or any lumbar puncture procedure performed for any reason in the previous 30 days